Skip to content
MARKETS / NASDAQ / ACB
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Aurora Cannabis Inc. ACB

7 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 343.3M
▲ 27.3% YoY
CAD 1.6M
In brief

What this company does

Aurora produces, distributes and sells cannabis products in Canada and internationally. It operates a 212,000 square foot indoor cultivation facility in Bradford, Ontario, acquired in July 2018 through the acquisition of MedReleaf. It also operates a 58,000 square foot facility in Markham, Ontario, acquired through the acquisition of MedReleaf. In Germany, Aurora is one of three active in-country producers of medical cannabis, holding a production and R&D license under German cannabis law. As of March 31, 2026, the Company, including its global subsidiaries, had approximately 1,028 employees. It conducts three key business activities: production, distribution and sale of medical cannabis products, and, on a limited basis, consumer cannabis products, in Canada; production and distribution of wholesale medical cannabis in the European Union; and distribution of wholesale medical cannabis in international markets including Australia, New Zealand, and the Caribbean.

Written from the business description in AURORA CANNABIS INC's annual report to the U.S. Securities and Exchange Commission, filed 11 June 2026. Every sentence was checked against that document before publication.

Growth
CAD 343.3M
Revenue, FY2024 · full 7-year series below
Revenue CAD B Net income CAD B
FY2024 · Revenue 0.3 · Net income 0.0
-2B2017201820192020202120232024
Compound annual growth
+15.8%
+5.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
0 cents
of every revenue dollar became profit
Operating margin Net margin
FY2024 · Operating 1.4% · Net 0.5%
-500%-1000%2017201820192020202120232024
ROE
FY2024 · ROE 0.3%
-50%-100%2017201820192020202120232024

Each CAD of equity produced 0 cents of profit this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2021 · FCF -142.5
-250.0M-500.0M2017201820192020202120232024

Total assetsCAD 852.7M
EquityCAD 567.2M
CashCAD 137.9M
Gross debtCAD 42.5M
Net debtCAD -95.4M
Current ratio4.31×

The company holds more cash than debt.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320212020201920182017
Revenue CAD B0.30.30.20.20.30.20.1
Operating income CAD B0.0−0.0−0.2−0.3−0.5−0.3−0.1
EBITDA CAD B0.0−0.0−0.2−0.2−0.4−0.3−0.1
Income tax CAD B0.0−0.0−0.0−0.0−0.1−0.00.0
Net income CAD B0.0−0.1−1.7−0.7−3.3−0.30.1
Free cash flow CAD B··−0.1−0.3·−0.6−0.2
EPS, diluted CAD 0.04−1.52−7.99−4.10·−0.290.15
Dividend / sh CAD ·······
Payout %·······
ROE %0.3−12.4−127.3−33.1−100.5−9.94.6

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 27 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 49 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsMarch 31
SEC categoryemerging growth company
Data on record since2017

Share this section

Download image